Difference between revisions of "Dabigatran (Pradaxa)"
(updated content) |
m |
||
| Line 17: | Line 17: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
| − | [[Category: | + | [[Category:Anticoagulants]] |
[[Category:Direct thrombin inhibitors]] | [[Category:Direct thrombin inhibitors]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2010]] | ||
Revision as of 15:16, 3 November 2014
Also known as Pradax or Prazaxa.
General information
Class/mechanism: Competitive direct thrombin inhibitor. Inhibition of thrombin, a serine protease, inhibits the conversion of fibrinogen into fibrin in the coagulation cascade and subsequent development of thrombus. Dabigatran inhibits free thrombin, clot-bound thrombin, and thrombin-induced platelet aggregation.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Dabigatran (Pradaxa) package insert pages 11-15[1]
- Dabigatran (Pradaxa) patient drug information (UpToDate)[4]